Covered recipient · General Payments record
AFSHIN GABAYAN
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$3,187.22
237 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $3,151.33 | 234 |
| Education | $35.89 | 3 |
By paying entity
PY2019 · entire year · sorted by reported total
Page 4 of 5; records 151–200 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
AFSHIN GABAYAN
NPI 1659412757 · CMS profile ID 75537
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
BEVERLY HILLS, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 5; records 151–200 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1659412757?year=2019&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- AFSHIN GABAYAN, NPI 1659412757, CMS profile ID 75537. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659412757?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). AFSHIN GABAYAN, NPI 1659412757, CMS profile ID 75537. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659412757?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- AFSHIN GABAYAN, NPI 1659412757, CMS profile ID 75537, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1659412757?year=2019&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
237 matching records · $3,187.22 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–200 of 237.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| PFIZER INC. | $12.19 | 05/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673796113 | CMS |
| PFIZER INC. | $3.49 | 05/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673798527 | CMS |
| PFIZER INC. | $1.48 | 05/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673813961 | CMS |
| Novartis Pharmaceuticals Corporation | $17.22 | 05/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659548225 | CMS |
| Celgene Corporation | $29.99 | 05/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672798117 | CMS |
| E.R. Squibb & Sons, L.L.C. | $12.55 | 05/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651275789 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2.45 | 05/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651275791 | CMS |
| EISAI INC. | $14.37 | 04/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697006999 | CMS |
| Puma Biotechnology, Inc. | $22.98 | 04/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 706019481 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $20.75 | 04/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 665702797 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.34 | 04/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685338423 | CMS |
| Janssen Biotech, Inc. | $17.19 | 04/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658435457 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2.73 | 04/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651275779 | CMS |
| E.R. Squibb & Sons, L.L.C. | $15.51 | 04/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651275781 | CMS |
| Genentech USA, Inc. | $21.98 | 04/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681195139 | CMS |
| Genentech USA, Inc. | $0.14 | 04/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681248487 | CMS |
| Genentech USA, Inc. | $2.21 | 04/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681315887 | CMS |
| Novartis Pharmaceuticals Corporation | $13.92 | 04/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659548223 | CMS |
| Incyte Corporation | $15.38 | 04/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 666260253 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $1.13 | 04/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697386981 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $21.94 | 04/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697386989 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $5.46 | 04/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697412109 | CMS |
| Janssen Biotech, Inc. | $23.51 | 03/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658435451 | CMS |
| Amgen Inc. | $23.07 | 03/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662150373 | CMS |
| Merck Sharp & Dohme Corporation | $19.88 | 03/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695389929 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2.30 | 03/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651275767 | CMS |
| E.R. Squibb & Sons, L.L.C. | $7.61 | 03/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651275769 | CMS |
| E.R. Squibb & Sons, L.L.C. | $0.21 | 03/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651275777 | CMS |
| Novartis Pharmaceuticals Corporation | $12.86 | 03/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659548221 | CMS |
| Teva Pharmaceuticals USA, Inc. | $16.93 | 03/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697776433 | CMS |
| Novartis Pharmaceuticals Corporation | $17.95 | 03/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659548203 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.35 | 03/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685391173 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2.82 | 03/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651275759 | CMS |
| E.R. Squibb & Sons, L.L.C. | $10.78 | 03/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651275765 | CMS |
| E.R. Squibb & Sons, L.L.C. | $0.23 | 03/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651275775 | CMS |
| PFIZER INC. | $13.30 | 03/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673798067 | CMS |
| EISAI INC. | $21.52 | 03/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697001265 | CMS |
| PFIZER INC. | $14.89 | 03/05/2019 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673801847 | CMS |
| PFIZER INC. | $11.05 | 03/05/2019 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673802541 | CMS |
| PFIZER INC. | $2.33 | 03/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673816581 | CMS |
| Incyte Corporation | $18.90 | 03/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 666260183 | CMS |
| PFIZER INC. | $14.55 | 02/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673798169 | CMS |
| PFIZER INC. | $2.15 | 02/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673821733 | CMS |
| Janssen Biotech, Inc. | $18.04 | 02/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658435443 | CMS |
| PFIZER INC. | $12.34 | 02/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673799149 | CMS |
| PFIZER INC. | $1.71 | 02/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673801835 | CMS |
| PFIZER INC. | $1.54 | 02/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673816593 | CMS |
| Genentech USA, Inc. | $22.28 | 02/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681295253 | CMS |
| Seattle Genetics, Inc. | $22.88 | 02/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 678804245 | CMS |
| Amgen Inc. | $30.70 | 02/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662150377 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,046.17 | 4 |
| PY2025 | Principal investigator | $3,611,094.02 | 289 |
| PY2024 | Recipient | $1,880.00 | 2 |
| PY2024 | Principal investigator | $2,546,132.13 | 153 |
| PY2023 | Recipient | $4,800.00 | 4 |
| PY2023 | Principal investigator | $2,392,774.59 | 194 |
| PY2022 | Principal investigator | $3,229,541.26 | 109 |
| PY2021 | Recipient | $1,270.00 | 2 |
| PY2021 | Principal investigator | $974,553.33 | 64 |
| PY2020 | Principal investigator | $529,226.71 | 49 |
| PY2019 | Principal investigator | $437,466.07 | 53 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
293 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $96.00 | 12/31/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting | No dispute reported | 06/30/2026 | 1202534245 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $133.41 | 12/31/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220773067 |
| Principal investigator 1 | PFIZER INC. | $12,452.07 | 12/31/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228815812 |
| Principal investigator 1 | PFIZER INC. | $10,980.90 | 12/31/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228816353 |
| Principal investigator 1 | Coherus Oncology, Inc. | $2,041.00 | 12/23/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | CHS38802 | No dispute reported | 06/30/2026 | 1235252290 |
| Principal investigator 1 | Coherus Oncology, Inc. | $1,899.00 | 12/23/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | CHS38802 | No dispute reported | 06/30/2026 | 1235252295 |
| Principal investigator 1 | Coherus Oncology, Inc. | $2,041.00 | 12/23/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | CHS38802 | No dispute reported | 06/30/2026 | 1235252387 |
| Principal investigator 1 | Coherus Oncology, Inc. | $2,041.00 | 12/23/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | CHS38802 | No dispute reported | 06/30/2026 | 1235252390 |
| Principal investigator 1 | PFIZER INC. | $23,971.08 | 12/23/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228717427 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $91.00 | 12/19/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912211 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $5,740.00 | 12/19/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912239 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $5,740.00 | 12/19/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912331 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $33,000.00 | 12/19/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | ALI-1201 | No dispute reported | 06/30/2026 | 1251753320 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $91.00 | 12/17/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912261 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $186.20 | 12/17/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912285 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $58.30 | 12/17/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220998593 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $19.98 | 12/17/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220998595 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $73.00 | 12/17/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220998597 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1.83 | 12/17/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220998599 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $20.50 | 12/17/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220998601 |
| Principal investigator 1 | PFIZER INC. | $2,000.00 | 12/17/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228715737 |
| Principal investigator 1 | PFIZER INC. | $3,683.93 | 12/17/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228816077 |
| Principal investigator 1 | PFIZER INC. | $12,881.70 | 12/17/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228816566 |
| Principal investigator 1 | PFIZER INC. | $11,861.60 | 12/16/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228816836 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $75.60 | 12/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912197 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $49.00 | 12/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912199 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $162.40 | 12/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912205 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $49.00 | 12/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912209 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $166.60 | 12/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912219 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $65.80 | 12/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912225 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $273.00 | 12/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912231 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $81.20 | 12/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912233 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $299.60 | 12/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912235 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $71.40 | 12/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912247 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $42.00 | 12/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912251 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $145.60 | 12/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912255 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $85.40 | 12/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912259 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $91.00 | 12/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912291 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $166.60 | 12/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912293 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $315.00 | 12/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912297 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $91.00 | 12/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912299 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $186.20 | 12/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912309 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $49.00 | 12/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912313 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $299.60 | 12/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912315 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $420.00 | 12/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912317 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $49.00 | 12/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912321 |
| Principal investigator 1 | PFIZER INC. | $465.75 | 12/11/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB PF06863135 A BCELL MATURATION ANTIGEN BCMA CD3 BISPECIFIC ANTIBODY IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228816422 |
| Principal investigator 1 | PFIZER INC. | $13,258.35 | 12/09/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228815515 |
| Recipient | ABBVIE INC. | $80.21 | 12/05/2025 | Covered Recipient Physician | Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma (CERVINO) | No dispute reported | 06/30/2026 | 1202398214 |
| Recipient | ABBVIE INC. | $15.96 | 12/05/2025 | Covered Recipient Physician | Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202398218 |
| Principal investigator 1 | ABBVIE INC. | $7,350.00 | 12/05/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202529304 |
| Principal investigator 1 | PFIZER INC. | $12,136.72 | 12/03/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228715827 |
| Principal investigator 1 | PFIZER INC. | $9,060.00 | 12/03/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228815876 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $119.00 | 12/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912201 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $210.00 | 12/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912203 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $280.00 | 12/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912207 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $210.00 | 12/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912213 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $300.00 | 12/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912215 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $280.00 | 12/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912217 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $182.00 | 12/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912221 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $280.00 | 12/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912223 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $280.00 | 12/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912237 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $300.00 | 12/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912249 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $119.00 | 12/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912253 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $300.00 | 12/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912257 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $259.00 | 12/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912287 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $329.00 | 12/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912289 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $280.00 | 12/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912295 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $560.00 | 12/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912301 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $280.00 | 12/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912303 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $259.00 | 12/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912305 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $259.00 | 12/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912307 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $259.00 | 12/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912311 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $280.00 | 12/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912319 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $280.00 | 12/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912323 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $280.00 | 12/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912325 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $280.00 | 12/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912327 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $119.00 | 12/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912329 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 12/01/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228719163 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $133.41 | 11/30/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220773065 |
| Principal investigator 1 | PFIZER INC. | $16,146.00 | 11/27/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228712554 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 11/27/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228717447 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,395.00 | 11/26/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220814513 |
| Principal investigator 1 | PFIZER INC. | $162.00 | 11/26/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB PF06863135 A BCELL MATURATION ANTIGEN BCMA CD3 BISPECIFIC ANTIBODY IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228712556 |
| Principal investigator 1 | PFIZER INC. | $1,068.45 | 11/26/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228818582 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $328.00 | 11/24/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220814501 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,395.00 | 11/24/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220814503 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,395.00 | 11/24/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220814505 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,395.00 | 11/24/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220814507 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $184.00 | 11/24/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220814509 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $112.18 | 11/24/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220814511 |
| Principal investigator 1 | PFIZER INC. | $23,971.08 | 11/24/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228717449 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $7,672.00 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912151 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,758.00 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912153 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $140.00 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912155 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $91.00 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912157 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,758.00 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912159 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $7,672.00 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912161 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $315.00 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912163 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $6,648.60 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912165 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $175.00 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912167 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $350.00 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912169 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $49.00 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912171 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,998.80 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912173 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,758.00 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912175 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $49.00 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912177 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $546.00 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912179 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $91.00 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912181 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $42.00 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912183 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $7,672.00 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912185 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $49.00 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912187 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $35.00 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912189 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $630.00 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912191 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $91.00 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912193 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $420.00 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912195 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $182.00 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912229 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $6,648.60 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912241 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $105.00 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912243 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $49.00 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912245 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,998.80 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912263 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $186.20 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912265 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,758.00 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912267 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $5,600.00 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912269 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $6,438.60 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912271 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $91.00 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912273 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,998.80 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912275 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,998.80 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912277 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,758.00 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912279 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,758.00 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912281 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $6,648.60 | 11/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912283 |
| Principal investigator 1 | PFIZER INC. | $35,371.90 | 11/18/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228712286 |
| Principal investigator 1 | PFIZER INC. | $48,832.20 | 11/14/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228715999 |
| Principal investigator 1 | PFIZER INC. | $12,287.72 | 11/14/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228716001 |
| Principal investigator 1 | PFIZER INC. | $3,330.01 | 11/14/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228818848 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $49.00 | 11/13/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912227 |
| Recipient | PFIZER INC. | $620.00 | 11/10/2025 | Covered Recipient Physician | ELRANATAMAB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228802909 |
| Principal investigator 1 | ABBVIE INC. | $11,500.00 | 11/05/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202521667 |
| Principal investigator 1 | PFIZER INC. | $12,136.72 | 11/05/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228715903 |
| Principal investigator 1 | PFIZER INC. | $50.69 | 11/04/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228818623 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $133.41 | 10/31/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220773061 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,246.94 | 10/30/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220814497 |
| Principal investigator 1 | PFIZER INC. | $23,971.08 | 10/28/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228717407 |
| Principal investigator 1 | PFIZER INC. | $82,611.90 | 10/28/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228825745 |
| Principal investigator 1 | PFIZER INC. | $3,957.93 | 10/24/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228826078 |
| Principal investigator 1 | PFIZER INC. | $1,008.45 | 10/21/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228825521 |
| Principal investigator 1 | PFIZER INC. | $45,512.70 | 10/20/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228715739 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $34,950.68 | 10/15/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS, LLC | a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton | No dispute reported | 06/30/2026 | 1185552551 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $92.00 | 10/15/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220814491 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $487.00 | 10/15/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220814493 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $92.00 | 10/15/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220814495 |
| Principal investigator 1 | PFIZER INC. | $59,023.90 | 10/15/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228825664 |
| Principal investigator 1 | ABBVIE INC. | $5,750.00 | 10/09/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202513715 |
| Principal investigator 1 | PFIZER INC. | $2,744.75 | 10/09/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228825048 |
| Principal investigator 1 | PFIZER INC. | $7,411.48 | 10/09/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228825342 |
| Principal investigator 1 | PFIZER INC. | $12,136.72 | 10/08/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228715825 |
| Principal investigator 1 | PFIZER INC. | $35,371.90 | 10/08/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center Optima Diagnostic Imaging | A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228717405 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $466.91 | 10/07/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220814499 |
| Principal investigator 1 | PFIZER INC. | $23,971.08 | 10/03/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228717425 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $133.41 | 09/30/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220773059 |
| Principal investigator 1 | PFIZER INC. | $56,386.80 | 09/26/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228836487 |
| Principal investigator 1 | ABBVIE INC. | $21,840.00 | 09/25/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202512390 |
| Principal investigator 1 | PFIZER INC. | $12,501.20 | 09/24/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228835695 |
| Principal investigator 1 | PFIZER INC. | $465.75 | 09/24/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB PF06863135 A BCELL MATURATION ANTIGEN BCMA CD3 BISPECIFIC ANTIBODY IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228836434 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 09/24/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228836497 |
| Principal investigator 1 | PFIZER INC. | $6,555.69 | 09/19/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228835672 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $3,287.00 | 09/17/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912137 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $8,800.00 | 09/17/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912139 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $5,000.00 | 09/17/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912141 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $60,000.00 | 09/17/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912143 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $9,000.00 | 09/17/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912145 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,250.00 | 09/17/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912147 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $10,000.00 | 09/17/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels | No dispute reported | 06/30/2026 | 1199912149 |
| Principal investigator 1 | Coherus Oncology, Inc. | $1,899.00 | 09/16/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | CHS38802 | No dispute reported | 06/30/2026 | 1235252299 |
| Principal investigator 1 | Coherus Oncology, Inc. | $1,208.00 | 09/16/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | CHS38802 | No dispute reported | 06/30/2026 | 1235252303 |
| Principal investigator 1 | PFIZER INC. | $15,635.70 | 09/16/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228835638 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 09/15/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228719090 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 09/14/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228717471 |
| Principal investigator 1 | PFIZER INC. | $12,136.72 | 09/10/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228715657 |
| Principal investigator 1 | PFIZER INC. | $21,223.14 | 09/08/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center Optima Diagnostic Imaging | A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228717409 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $26,590.00 | 09/04/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220814477 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $442.28 | 09/03/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220814479 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,895.69 | 09/03/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220814481 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $16,212.92 | 09/03/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220814483 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $459.24 | 09/03/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220814485 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17,750.00 | 09/03/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220814487 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $395.00 | 09/03/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220814489 |
| Principal investigator 1 | PFIZER INC. | $23,971.08 | 09/03/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228717445 |
| Principal investigator 1 | PFIZER INC. | $5,436.85 | 09/03/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228836426 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $133.41 | 08/31/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220773063 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $53.67 | 08/26/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220998583 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $151.58 | 08/26/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220998585 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $219.00 | 08/26/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220998587 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3.66 | 08/26/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220998589 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $46.00 | 08/26/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220998591 |
| Principal investigator 1 | PFIZER INC. | $2,560.95 | 08/23/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228842831 |
| Principal investigator 1 | PFIZER INC. | $3,957.93 | 08/23/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228842837 |
| Principal investigator 1 | PFIZER INC. | $162.00 | 08/22/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB PF06863135 A BCELL MATURATION ANTIGEN BCMA CD3 BISPECIFIC ANTIBODY IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228843729 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,500.00 | 08/20/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | A PHASE I STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF BELANTA | No dispute reported | 06/30/2026 | 1192185962 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,500.00 | 08/20/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | A PHASE I STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF BELANTA | No dispute reported | 06/30/2026 | 1192185965 |
| Principal investigator 1 | PFIZER INC. | $9,262.01 | 08/14/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228843405 |
| Principal investigator 1 | PFIZER INC. | $81,041.05 | 08/14/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228843668 |
| Principal investigator 1 | PFIZER INC. | $2,217.44 | 08/14/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228843738 |
| Principal investigator 1 | PFIZER INC. | $12,136.72 | 08/13/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228716003 |
| Principal investigator 1 | PFIZER INC. | $23,971.08 | 08/07/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228717469 |
| Recipient | PFIZER INC. | $330.00 | 08/05/2025 | Covered Recipient Physician | ELRANATAMAB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228802915 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,421.00 | 08/02/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220814469 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,421.00 | 08/02/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220814471 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $426.00 | 08/02/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220814473 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,421.00 | 08/02/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220814475 |
| Principal investigator 1 | PFIZER INC. | $10,999.39 | 08/02/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228843746 |
| Principal investigator 1 | Coherus Oncology, Inc. | $6,957.00 | 07/31/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | CHS38802 | No dispute reported | 06/30/2026 | 1235252286 |
| Principal investigator 1 | PFIZER INC. | $3,478.43 | 07/25/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228847404 |
| Principal investigator 1 | PFIZER INC. | $1,768.20 | 07/25/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228847420 |
| Principal investigator 1 | PFIZER INC. | $5,824.15 | 07/25/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228847493 |
| Principal investigator 1 | Coherus Oncology, Inc. | $994.81 | 07/23/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | CHS38802 | No dispute reported | 06/30/2026 | 1235252307 |
| Principal investigator 1 | PFIZER INC. | $18,205.08 | 07/16/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228715655 |
| Principal investigator 1 | PFIZER INC. | $38,403.45 | 07/16/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228847501 |
| Principal investigator 1 | PFIZER INC. | $32,277.25 | 07/16/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228847555 |
| Principal investigator 1 | PFIZER INC. | $36,450.00 | 07/11/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB PF06863135 A BCELL MATURATION ANTIGEN BCMA CD3 BISPECIFIC ANTIBODY IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228847337 |
| Principal investigator 1 | PFIZER INC. | $631.56 | 07/11/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228847484 |
| Principal investigator 1 | PFIZER INC. | $21,239.26 | 07/07/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228716077 |
| Principal investigator 1 | PFIZER INC. | $2,700.96 | 07/01/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228847414 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $133.41 | 06/30/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220773057 |
| Principal investigator 1 | PFIZER INC. | $40,748.42 | 06/27/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228851492 |
| Principal investigator 1 | PFIZER INC. | $25,490.70 | 06/27/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228851507 |
| Principal investigator 1 | PFIZER INC. | $17,599.90 | 06/27/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228852155 |
| Principal investigator 1 | Coherus Oncology, Inc. | $110,250.00 | 06/26/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | CHS38802 | No dispute reported | 06/30/2026 | 1235252280 |
| Principal investigator 1 | PFIZER INC. | $627.75 | 06/26/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB PF06863135 A BCELL MATURATION ANTIGEN BCMA CD3 BISPECIFIC ANTIBODY IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228852167 |
| Principal investigator 1 | PFIZER INC. | $15,047.54 | 06/26/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228852217 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $143,263.23 | 06/23/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS, LLC | Artemide Lung02 a phase III global study of rilvegostomig or pembrolizumab for patients with metastatic squamous non small cell lung cancer | No dispute reported | 06/30/2026 | 1185552555 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 06/23/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228822520 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 06/22/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228833878 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $115,700.00 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS, LLC | A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic NSCLC With High PD-L1 Expression and Without Actionable Genomic Alterations (TROPION-Lung10) | No dispute reported | 06/30/2026 | 1185552557 |
| Principal investigator 1 | PFIZER INC. | $35,371.90 | 06/17/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228842134 |
| Principal investigator 1 | PFIZER INC. | $30,341.80 | 06/16/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228842166 |
| Principal investigator 1 | PFIZER INC. | $15,645.60 | 06/14/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228852225 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $240,351.58 | 06/13/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS, LLC | A Phase III Randomized Double blind Multicenter Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum based Chemotherapy for the First line Treatment of Patients with Metastatic Non squamous Non small Cell Lung Cancer Whose Tumors Express PDL1 ARTEMIDE Lung03 | No dispute reported | 06/30/2026 | 1185552553 |
| Principal investigator 1 | PFIZER INC. | $2,560.95 | 06/07/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228851501 |
| Principal investigator 1 | PFIZER INC. | $12,136.72 | 06/04/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228842149 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $133.41 | 05/31/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220773055 |
| Principal investigator 1 | PFIZER INC. | $2,780.25 | 05/28/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228858281 |
| Principal investigator 1 | PFIZER INC. | $14,996.85 | 05/23/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228858196 |
| Principal investigator 1 | PFIZER INC. | $1,831.95 | 05/23/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB PF06863135 A BCELL MATURATION ANTIGEN BCMA CD3 BISPECIFIC ANTIBODY IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228858202 |
| Principal investigator 1 | PFIZER INC. | $2,832.30 | 05/23/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228858274 |
| Principal investigator 1 | PFIZER INC. | $12,136.72 | 05/21/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228842172 |
| Principal investigator 1 | PFIZER INC. | $8,398.35 | 05/14/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228858213 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $113,250.00 | 05/01/2025 | Non-covered Recipient Entity Clinical Research Advisors LLC | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220814467 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $133.41 | 04/30/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220773053 |
| Principal investigator 1 | PFIZER INC. | $5,858.45 | 04/29/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228859914 |
| Principal investigator 1 | PFIZER INC. | $4,365.90 | 04/29/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228859962 |
| Principal investigator 1 | PFIZER INC. | $467.10 | 04/25/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB PF06863135 A BCELL MATURATION ANTIGEN BCMA CD3 BISPECIFIC ANTIBODY IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228860556 |
| Principal investigator 1 | PFIZER INC. | $5,863.14 | 04/24/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228858148 |
| Principal investigator 1 | PFIZER INC. | $2,000.00 | 04/23/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228842144 |
| Principal investigator 1 | PFIZER INC. | $324.00 | 04/16/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB PF06863135 A BCELL MATURATION ANTIGEN BCMA CD3 BISPECIFIC ANTIBODY IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228859569 |
| Principal investigator 1 | PFIZER INC. | $10,064.25 | 04/16/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228859577 |
| Principal investigator 1 | PFIZER INC. | $11,942.26 | 04/16/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228859905 |
| Principal investigator 1 | PFIZER INC. | $15,871.19 | 04/08/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228858138 |
| Principal investigator 1 | PFIZER INC. | $1,008.45 | 04/08/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228859582 |
| Principal investigator 1 | PFIZER INC. | $4,296.55 | 04/01/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB PF06863135 A BCELL MATURATION ANTIGEN BCMA CD3 BISPECIFIC ANTIBODY IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228859600 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $133.41 | 03/31/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220773051 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 03/31/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228822526 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 03/30/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228833885 |
| Principal investigator 1 | PFIZER INC. | $12,536.10 | 03/28/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228862153 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,000.00 | 03/25/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | A PHASE I STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF BELANTA | No dispute reported | 06/30/2026 | 1192185951 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $12,250.00 | 03/25/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | A PHASE I STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF BELANTA | No dispute reported | 06/30/2026 | 1192185957 |
| Principal investigator 1 | PFIZER INC. | $54,521.62 | 03/22/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228862168 |
| Principal investigator 1 | PFIZER INC. | $6,704.20 | 03/22/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB PF06863135 A BCELL MATURATION ANTIGEN BCMA CD3 BISPECIFIC ANTIBODY IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228863042 |
| Principal investigator 1 | PFIZER INC. | $2,560.95 | 03/22/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228863048 |
| Principal investigator 1 | PFIZER INC. | $30,273.75 | 03/14/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228862177 |
| Principal investigator 1 | PFIZER INC. | $110,805.01 | 03/04/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228863059 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $133.41 | 02/28/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220773049 |
| Principal investigator 1 | PFIZER INC. | $2,713.50 | 02/27/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB PF06863135 A BCELL MATURATION ANTIGEN BCMA CD3 BISPECIFIC ANTIBODY IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228836422 |
| Principal investigator 1 | PFIZER INC. | $48,406.15 | 02/26/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228836492 |
| Principal investigator 1 | PFIZER INC. | $17,700.71 | 02/22/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228835631 |
| Principal investigator 1 | ABBVIE INC. | $3,500.00 | 02/20/2025 | Non-covered Recipient Entity CLINICAL RESEARCH ADVISORS LLC | M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202452894 |
| Principal investigator 1 | PFIZER INC. | $28,297.52 | 02/03/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center Optima Diagnostic Imaging | A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228834648 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $133.41 | 01/31/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220773047 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,000.00 | 01/30/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | Phase Ib/expansion BI836880 in combination with CPI | No dispute reported | 06/30/2026 | 1220792041 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $35.78 | 01/27/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220998569 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $151.58 | 01/27/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220998571 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $79.92 | 01/27/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220998573 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $219.00 | 01/27/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220998575 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $5.60 | 01/27/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220998577 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $12.20 | 01/27/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220998579 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $59.00 | 01/27/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) | No dispute reported | 06/30/2026 | 1220998581 |
| Principal investigator 1 | PFIZER INC. | $1,279.80 | 01/25/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228862592 |
| Principal investigator 1 | PFIZER INC. | $50,961.00 | 01/24/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228863510 |
| Principal investigator 1 | PFIZER INC. | $117,105.75 | 01/15/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228863516 |
| Principal investigator 1 | PFIZER INC. | $2,713.50 | 01/15/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB PF06863135 A BCELL MATURATION ANTIGEN BCMA CD3 BISPECIFIC ANTIBODY IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1228863526 |
| Principal investigator 1 | AstraZeneca UK Limited | $163,446.40 | 01/13/2025 | Non-covered Recipient Entity BEVERLY HILLS CANCER CENTER | A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) | No dispute reported | 06/30/2026 | 1185552559 |
| Principal investigator 1 | Janssen Research & Development, LLC | $334.00 | 01/13/2025 | Non-covered Recipient Entity Sarah Cannon Rsrch Inst Llc | A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy | No dispute reported | 06/30/2026 | 1175273759 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 01/06/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228822532 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 01/05/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228834641 |